Author:
Li Xiaoyu,Chen Qin,Yu Xiaobing
Abstract
Abstract
Purpose
To investigate early changes in the intraocular pressure (IOP) and macular microvascular structure in eyes with branch retinal vein occlusion (BRVO) treated with intravitreal Ranibizumab injection.
Methods
This study enrolled 30 patients (one eye per patient) who received intravitreal injections (IVI) of ranibizumab for macular edema secondary to BRVO. IOP were measured before, 30 min (min) and 1 month following IVI. Changes in macular microvascular structure were examined via assessment of foveal avascular zone (FAZ) parameters, vascular density (VD) of superficial vascular complex (SVC), and deep vascular complex (DVC) in whole macula, central fovea and parafovea area which were measured automatically by optical coherence tomography angiography (OCTA) on the same time as IOP examinations. Paired t test and Wilcoxon test were used to compare pre- and post-injection values. The correlation between IOP and OCTA findings was assessed.
Results
IOP Measurements at 30 min post-IVI (17.91 ± 3.36 mmHg) increased significantly from baseline (15.07 ± 2.58 mmHg, p < 0.001), then became similar with baseline after 1 month (15.00 ± 3.16 mmHg, p = 0.925). 30 min past the injection, the parameters of VD of the SCP significantly decreased in comparison to baseline, then became similar with baseline after one month, while there were no significant changes in other OCTA parameters, including parameters of VD of the DCP and the FAZ. At 1 month after IVI, in comparison to baseline, no significant changes were observed in all of the OCTA parameters (P > 0.05). There were no significant correlations between IOP and OCTA findings no matter 30 min or 1 month post-IVI (P > 0.05).
Conclusions
Transient IOP elevation and decreased superficial macular capillary perfusion density were detected 30 min post-IVI, however, no potential continual macular microvascular damage was suspected.
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology,General Medicine
Reference32 articles.
1. Rogers SL, McIntosh RL, Lim L et al. “Natural history of branch retinal vein occlusion: an evidence-based systematic review, “Ophthalmology, vol. 117, no. 6, pp.1094–1101, 2010.
2. Ho M, Liu DTL, Lam DSC, Jonas JB. Retinal vein occlusions, from basics to the latest treatment. Retina. 2016;36(3):432–48.
3. Gerding H, Mones J, Tadayoni R, Boscia F, Pearce I, Priglinger ´S. Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. Br J Ophthalmol. 2015;99(3):297–304.
4. Song S, Yu X, Dai H. The efficacy of combination of intravitreal ranibizumab with triamcinolone or laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Chin J Ocular Fundus Dis. 2015;31:18–21.
5. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. “Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion,”Retina, vol. 27, no. 4, pp.419–425,2007.